Friday, 31 July 2015

Ophthalmic Drugs Market to be Valued at US$21.6 Billion by 2018 due to Increasing Prevalence of Eye Disorders

Transparency Market Research’s report on the global ophthalmic drugs market offers a detailed segmentation of this market. The report is titled “Ophthalmic Drugs Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2018”. The TMR report states that the global ophthalmic drugs market will expand at a CAGR of 5.2% during the forecast period of 2013 to 2018. By 2018, the market is expected to be worth US$21.6 billion; in 2012, this market was valued at US$16 billion.Globally, the demand for ophthalmic drugs in the form of ointments and drops is rising due to the increasing prevalence of eye disorders. The top reasons for blindness and other vision defects in the U.S. are age-related conditions such as cataract, glaucoma, diabetic retinopathy, and age-related macular degeneration. Thus, the accelerating geriatric population will also drive the demand for ophthalmic drugs worldwide.

Browse the full Ophthalmic Drugs Market Report at http://www.transparencymarketresearch.com/ophthalmic-drugs-market.html


Apart from these primary factors, the increasing number of government initiatives to improve healthcare infrastructure in emerging nations will also drive the global ophthalmic drugs market. Furthermore, the technological advancements in drug delivery techniques, such as noninvasive techniques, and the rising prevalence of lifestyle-related medical conditions will also drive the global ophthalmic drugs market.The global ophthalmic drugs market will also benefit from the elevated focus on combination therapy. Combination therapy offers several advantages over the conventional approach, such as improved patient compliance, enhanced efficacy, and reduced frequency of eye drop application.

By treatment drugs, the global ophthalmic drugs market is divided into anti-glaucoma drugs, anti-inflammatory/infective/allergy drugs, retinal drugs, and dry eye drugs. Glaucoma dominates the global ophthalmic drugs market and is projected to demonstrate a CAGR of 4.2% during the forecasting horizon. By drug type, the global ophthalmic drugs market is segmented into OTC (over-the-counter) drugs and prescription drugs.By geography, the global ophthalmic drugs market is divided into North America, Asia Pacific, Europe, and Rest of the World. Currently, North America is the largest market for ophthalmic drugs. On the other hand, Asia Pacific is the fastest growing regional market. Country-wise, China and India are two of the fastest growing markets in the global ophthalmic drugs market.

Developed countries of North America and Europe are expected to show good growth in demand from the global ophthalmic drugs market, due to the elevated efforts to prevent blindness among the geriatric population in these countries. The rising number of mergers and acquisitions in the market are expected to contribute to the growth of the global ophthalmic drugs market. Recently, Allergan added an eye specialist firm called Oculeve to its portfolio. In 2012, Novartis (Alcon) led the global ophthalmic drugs market with an impressive market share of 24%. Other key players operating in the global ophthalmic drugs market include Pfizer, Allergan, Merck and Roche, and Santen.Even though the global ophthalmic drugs market will demonstrate positive growth in the foreseeable future, it will be constrained to an extent by the drying pipeline for ophthalmic drugs and the lack of health insurance in emerging countries.




Ophthalmic Drugs Market, By Treatment Drugs
Dry Eye Drugs
Retinal Drugs
Anti-inflammatory/allergy/infective Drugs
Anti-glaucoma Drugs
Ophthalmic Drugs Market, By Types
Prescription Drugs
OTC Drugs
Ophthalmic Drugs Market, by Geography
North America
U.S.
Europe
Germany
U.K.
France
Asia Pacific
Japan
China
India
Rest of the World (RoW)



About Us

Transparency Market Research (TMR) is a global market intelligence company providing business information reports and services. The company’s exclusive blend of quantitative forecasting and trend analysis provides forward-looking insight for thousands of decision makers. TMR’s experienced team of analysts, researchers, and consultants use proprietary data sources and various tools and techniques to gather and analyze information.

TMR’s data repository is continuously updated and revised by a team of research experts so that it always reflects the latest trends and information. With extensive research and analysis capabilities, Transparency Market Research employs rigorous primary and secondary research techniques to develop distinctive data sets and research material for business reports.

Contact

Mr. Nachiket
State Tower,
90 State Street,
Suite 700,
Albany NY - 12207
United States
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453
Email: sales@transparencymarketresearch.com

Website: http://www.transparencymarketresearch.com
Posted by at No comments:
Labels:

Drugs of Abuse Testing Market to Exhibit Moderate 4.8% CAGR, Favorable Government Initiatives to Steer Global Market

Socioeconomic losses triggered by use of illicit drugs have raised global concerns. Government and non-government agencies of several nations have adopted several initiatives to curb the increasing incidence of drug abuse. This is expected to give momentum to the global drug abuse testing market. According to a report published by Transparency Market Research, the global drugs abuse testing market is projected to exhibit moderate expansion at a 4.8% CAGR between 2013 and 2018. The report is titled “Drugs of Abuse Testing Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 – 2018” and is available on Transparency Market Research’s website for sale. Not just production but trade of illicit drugs has also increased, which has spurred illicit drug consumption substantially. To counter the escalating consumption of illicit drugs, drugs of abuse testing is now being adopted at organizational levels. Additionally, the report mentions that the increasing death rates and rising number of road accidents due to drug abuse is expected to boost the global drugs of abuse testing market considerably.

Browse the full Drugs of Abuse Testing Market Report at http://www.transparencymarketresearch.com/drugs-abuse-testing-market.html


However, the society is yet to discard the stigma associated with the testing of illicit drugs, which is why the drugs of abuse testing market is encountering numerous obstacles. Complications associated with legalization of various drugs, cost concerns, and economic volatility are other factors which could emerge as potential threats to the market. Among the key geographical segments of the global drugs of abuse testing market, North America has demonstrated impressive growth in the adoption of drugs of abuse testing. The presence of the U.S. in North America has got the region the title of the fastest growing drugs of abuse testing market. Other leading markets for drugs of abuse testing are Germany, Japan, the U.K., and other European economies.

The UNODC (United Nations Office on Drugs and Crime) published a report in 2013, which states that the population of illicit drug users increased from 167 million in 2009 to 315 million in 2011. It represented 3.6% and 6.9% of worldwide adult population in the respective year. Studies have revealed that opiates, opioids, and cannabis are the most commonly consumed illicit drugs.



To combat the rising incidence of drug abuse, numerous organization across Europe and North America are conducting drug screening tests such as random drug or alcohol screening, pre-employment screening, abstinence monitoring, and post-incident screening at various levels. This has propelled the global drugs of abuse testing market significantly. Other factors such as favorable government initiatives supporting drugs of abuse testing, especially in countries such as Australia, Japan, the U.S., and the U.K., have also propelled the global market for drugs abuse testing. Among the segmentation based on sample, drug abuse testing from urine samples holds the largest share of the market. The segment is expected to expand at a 5.0% CAGR between 2013 and 2018. Drugs of abuse testing carried out using saliva and hair specimens has also gained significant impetus in recent times. The commercial availability of on-site screening test kits for drugs abuse testing have further boosted the global drugs abuse testing market.


The report profiles leading players in the market to measure the market’s competitiveness. Some of the companies profiled in the report are LabCorp, Quest Diagnostics, Abbott Laboratories, and Alere. The report identifies Roche Diagnostics as one of the most prominent players in the global drugs of abuse testing market.



About Us

Transparency Market Research (TMR) is a global market intelligence company providing business information reports and services. The company’s exclusive blend of quantitative forecasting and trend analysis provides forward-looking insight for thousands of decision makers. TMR’s experienced team of analysts, researchers, and consultants use proprietary data sources and various tools and techniques to gather and analyze information.

TMR’s data repository is continuously updated and revised by a team of research experts so that it always reflects the latest trends and information. With extensive research and analysis capabilities, Transparency Market Research employs rigorous primary and secondary research techniques to develop distinctive data sets and research material for business reports.

Contact

Mr. Nachiket
State Tower,
90 State Street,
Suite 700,
Albany NY - 12207
United States
USA - Canada Toll Free: 866-552-3453
Email: sales@transparencymarketresearch.com

Website: http://www.transparencymarketresearch.com
Posted by at No comments:
Labels:

Wednesday, 29 July 2015

Healthcare Information Systems Market to Post 7.1% CAGR from 2013–2019 with Progression of Integrated Healthcare Systems


The deepening interest in integrated healthcare systems will benefit the global healthcare information systems market, leading it to achieve a compounded annual growth rate (CAGR) of 7.1% between 2013 and 2019, says Transparency Market Research in its latest report. The report, titled ‘Healthcare Information System Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013–2019’ states that the market, will reach US$53.2 billion by 2019, growing strongly from its 2013 value of US$35.1 billion. The growth of the market is also propelled by an increase in the healthcare costs.The other market forces pinned down by the report are: An expansion in the aging population base, supportive government initiatives, and higher investments by companies in the healthcare IT market. In contrast, aspects that will impede the growth of the healthcare information systems market are identified as: A dearth of skilled and experienced professionals, high investment and maintenance costs of healthcare informatics, and interoperability glitches.

Browse the full Healthcare Information System Market Report at http://www.transparencymarketresearch.com/healthcare-information-system.html


Even as companies in the market try to address and alleviate the drawbacks of healthcare informatics, there are some remunerative opportunities that are already on the horizon. The foremost among these is wireless and cloud technology for healthcare informatics. These developments are the result of a paradigm shift from manual processes to computerized and automated processes. The burgeoning adoption of electronic health records and the growing use of mobile devices for monitoring and alerts is expected to create promising avenues for the growth of the healthcare information systems market.

An external trend that directly impacts the growth rate of the global healthcare information systems market is the increasing adoption of home health monitoring systems – the use of such systems was estimated to be 2.8 million in 2012. Wireless medical devices, too, are soon become a healthcare standard. Research studies state that in 2014, about 5.7 million patients were monitored via wireless medical devices.The report segments the healthcare information systems market by application mode as: Pharmacy information system, hospital information system, and laboratory information system. The largest among these is the hospital information systems segment, pegged to expand at a CAGR of 6.9% from 2013 to 2019. Likewise, by delivery mode, the market is classed as: On-premise technology, web-based technology, and cloud technology. The report also segments the healthcare information systems market by components as: Hardware, software, and services.


On the basis of geography, the healthcare information systems market is classified as North America, Asia, Europe, and Rest of the World (RoW).While North America is the global leader in the healthcare information systems market, Asia will report the healthiest rate of growth over the report’s forecast period, say TMR analysts. The Asian healthcare information systems market will benefit from developments in India, China, and Japan, whereas in North America, the United States will continue to fuel the market’s progress.The competitive landscape of the healthcare information systems market is still in a phase of change and growth, but is currently dominated by GE Healthcare. The other players that have an appreciable share in the market’s revenue are McKesson Corporation and Philips Healthcare.


The global healthcare information systems market is segmented as follows:

Healthcare Information Systems Market, by application mode
Hospital Information System
Pharmacy Information System
Laboratory Information System
Healthcare Information Systems Market, by delivery mode
Web based technology
On-premise technology
Cloud based technology
Healthcare Information Systems Market, by components
Software
Hardware
Services
Healthcare Information Systems Market, by geography
North America
U.S.
ROW
Asia
Japan
China
Europe
U.K.
Germany
France
Rest of the World (RoW)



About Us

Transparency Market Research (TMR) is a global market intelligence company providing business information reports and services. The company’s exclusive blend of quantitative forecasting and trend analysis provides forward-looking insight for thousands of decision makers. TMR’s experienced team of analysts, researchers, and consultants use proprietary data sources and various tools and techniques to gather and analyze information.


TMR’s data repository is continuously updated and revised by a team of research experts so that it always reflects the latest trends and information. With extensive research and analysis capabilities, Transparency Market Research employs rigorous primary and secondary research techniques to develop distinctive data sets and research material for business reports.
Posted by at No comments:
Labels:

Global Peptide Therapeutics Market to be Fueled by Increasing Prevalence of Cancer and Diabetes



The global market for peptide therapeutics market derives much of its demand from the treatment of cancer and diabetes. The rising incidence of these diseases is making way for the advancement of peptide drugs, which in turn is propelling the global peptide therapeutics market. Additionally, the technical advancements in peptide drugs have resulted in a reduction in total production cost, fueling the production process of new peptide drugs.

Browse Full Global Peptide Therapeutics Market Report With Complete TOC @ http://www.transparencymarketresearch.com/peptide-therapeutics-market.html


On the other hand, API manufacturers are facing a tough challenge from the complex structure of peptides. Other than this, the lack of regulatory standards to arbitrate developments in peptide drugs is also hampering the growth of the peptide therapeutics market. However, biotech enterprises are identifying prospects for future growth in collaboration with major pharmaceutical firms across the globe.The global peptide therapeutics market is expected to expand at a CAGR of 2.8% during the period from 2014 to 2020 in order to reach US$23.7 billion by 2020. The market had reached a value of US$18.9 billion in 2013.

Market for Respiratory Disorders Poised to Grow at Highest CAGR between 2014 and 2020

Peptide therapeutics find application in the treatment of various kinds of ailments such as cardiovascular, nervous, gastrointestinal, respiratory, metabolism-related, in addition to cancer, various infections, and pain. The cancer market was the dominant application segment of the peptide therapeutics market in 2013. However, the respiratory disorder market segment is projected to develop at the highest CAGR during the period from 2014 to 2020 owing to the recent approval of lucinactant, sold under the brand name Surfaxin.

The global peptide therapeutics market is analyzed on three fronts: Route of administration, marketing status, and regional distribution of the global industry. Based on route of administration, parenteral and oral are the two segments of this market, while branded peptide therapeutics and generic peptide therapeutics are the segments of the global market on the basis of marketing status. The market for generic peptides is expected to do well in the next few years on account of patent expirations expected in the branded peptide market in the near future.

Asia Pacific to Report Highest Compound Annual Growth Rate from 2014 to 2020

Regionally, the global peptide therapeutics market is distributed among North America, Europe, Asia Pacific, and the Rest of the World, wherein the global market is dominated by the North American and European markets, which jointly occupy over 60% of the global market. However, in spite of the dominance of these regions in the global market, the peptide therapeutics market in Asia Pacific is poised to grow at the highest CAGR during the period from 2014 to 2020.The peptide therapeutics market in Asia Pacific is majorly driven by the rapid growth of this market in China, India, and Japan. The rise in economic stability and increased awareness pertaining to the treatment of various diseases are the major factors fueling the growth of the market in this region.


Japan is the second largest market in the global individual pharmaceutical industry, whereas China and India have a huge population pool suffering from various diseases and ailments that are cured with the help of peptide therapeutics. These factors are expected to establish Asia Pacific as the most promising market for peptide therapeutics in the near future. China and India are also emerging as some of the largest peptide API suppliers in the world.

Amgen, Inc., Bachem Holding AG, AstraZeneca Plc, CordenPharma Int. GmbH, Ipsen S.A., Eli Lilly and Co., Lonza Group Ltd., Novartis AG, Merck & Co., Inc., Novo Nordisk A/S, Roche Holdings AG, PolyPeptide Group, Sanofi, Millennium Pharmaceuticals Inc., Teva Pharmaceutical Industries Ltd., and Takeda Pharmaceutical Co. Ltd. are the major enterprises working in the global peptide therapeutics industry. The market is mostly concentrated as Takeda, Teva, and Novo Nordisk collectively hold more than 50% of the overall peptide therapeutics market.

The forthcoming patent expiry of Copaxone by Teva and Velcade by Millennium Pharma and the projected launch of their generic alternatives are expected to change the dynamics of the global peptide therapeutics market in the near future.


About Us

Transparency Market Research (TMR) is a market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. We have an experienced team of Analysts, Researchers, and Consultants, who use proprietary data sources and various tools and techniques to gather, and analyze information. Our business offerings represent the latest and the most reliable information indispensable for businesses to sustain a competitive edge.

Each TMR Syndicated Research report covers a different sector — such as pharmaceuticals, chemical, energy, food & beverages, semiconductors, med-devices, consumer goods and technology. These reports provide in-depth analysis and deep segmentation to possible micro levels. With wider scope and stratified research methodology, our syndicated reports thrive to provide clients to serve their overall research requirement.

Contact

Mr. Nachiket Ghumare
90 State Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453
Email: sales@transparencymarketresearch.com

Website: http://www.transparencymarketresearch.com
Posted by at No comments:
Labels:

Meningococcal Disease Vaccines Market Set to Increase Due to Government and Private Healthcare Initiatives

Meningococcal disease is a catastrophic infection that spreads through the Neisseria meningitides bacteria. The disease occurs due to aggravation of the pathogenicity of the bacteria due to seasonal variations and is a life-threatening illness. Meningococcal disease occurs when meninges, the thin lining surrounding the brain and spinal cord, are severely infected. Vaccines for immunization have helped save millions of lives and are considered the most effective method of prevention of many communicable diseases.

Five serogroups of bacteria cause the invasive global meningococcal disease vaccines market. The serogroups mainly exist in humans in a dormant state and eventually cause the disease due to factors such as environment or immunogenic causes. The most prominent serogroups are A, B, C, Y, and W-135. The serogroups occur in variations based on age, geographical locations, and time. The disease can result in death within 24 hours from the onset of symptoms and is contagious. The disease has a high mortality rate and is fatal if not diagnosed or treated.

Browse Full Global Meningococcal Disease Vaccines Market Research Report With Complete TOC @ http://www.transparencymarketresearch.com/meningococcal-vaccines-market.html

Bexsero, Trumenba, NmVac4 DT Vaccines Lead Meningococcal Disease Vaccines Market

Vaccines are the best known preventive measures for meningococcal disease and there are vaccines available for prevention of meningitis, meningococcemia, and septicemia. Bexsero by Novartis and Trumenba by Pfizer are vaccines that have been recently approved in the U.S. in January 2015, and October 2014, respectively. Novartis was allowed to market Bexsero for serogroup B in Europe, Canada, and Australia. NmVac4 DT is a conjugate vaccine against meningococcal disease has been developed against the serogroups A, C, Y and W-135. This vaccine is animal component free, which could increase its demand post launch.

Vaccines for meningococcal disease include types such as combination vaccines, polysaccharide, and conjugate that are segmented into different brands. Among these, polysaccharide vaccines are the oldest available, being formulated three decades ago. Conjugate vaccines have been widely used and have significantly reduced the prevalence of bacterial meningitis due to the prolonged immunity achieved against the disease-causing serogroups, as compared to polysaccharide vaccines, which provide immunity for a very short period. The use of combination vaccines to combat two bacterial infections, for use against invasive meningococci, is being used effectively in the current scenario.




Increased Preventive Measures Fuel Market for Meningococcal Disease Vaccines

Due to the medical emergency status of the meningococcal disease, there is an increased demand for preventive vaccines. The increased number of people needing immunization and awareness campaigns run by governments, non-profit organizations, and manufacturers in developed economies have contributed to the increased demand for the vaccines. In certain countries, governments have introduced immunization programs for school children, Haj pilgrims, and sub-Saharan travelers resulting in increased demand for meningococcal vaccines. A recent market research study indicates that the global market for meningococcal vaccines was valued at US$1,537.3 million in 2013 and analysis shows an expected rise to US$4,450.4 million in 2022 at a CAGR of 12.4 % from 2014 to 2022.

Geographical distribution of the global meningococcal vaccines market includes four regions: North America, Europe, Asia Pacific, and Rest of the World (RoW). Major countries in these regions are part of the sub-segmentation of these areas. North America was the largest market for meningococcal vaccines in terms of revenue in 2013. The fastest growing market for the vaccines is considered to be Asia Pacific, followed by Rest of the World (RoW).



About Us

Transparency Market Research is a global market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. Our experienced team of Analysts, Researchers, and Consultants, use proprietary data sources and various tools and techniques to gather, and analyze information.

Our data repository is continuously updated and revised by a team of research experts, so that it always reflects the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.


Posted by at No comments:
Labels:

Tuesday, 28 July 2015

Global API Market to be hampered by Stern Regulatory Policies in European Union:Transparency Market Research


The recent patent expiry of several blockbuster drugs has presented specialized active pharmaceutical ingredients (API) manufacturers with ample opportunities for expansion all over the world. The bioactive portions of any drug are made up of APIs. The U.S. FDA defines APIs as a material or an amalgam of materials utilized in the manufacture of a drug and one that becomes an active ingredient of the drug upon production. APIs present patients with health benefits and assist in diagnosing, preventing, and curing diseases, though the result of and reactions to the drug vary from patient to patient depending on the dosage consumed.

Browse Full Global API Market Report With Complete TOC @ http://www.transparencymarketresearch.com/active-pharmaceutical-ingredients.html


In the recent past, the increase in abbreviated new drug applications has stimulated the demand for APIs. Additionally, several Indian pharmaceutical companies are joining the rapidly growing global API market. However, the stern regulatory policies in the European Union are restricting the rise of this market.

In 2013, the global API market had reached a value of US$119.7 billion. By 2020, the market is estimated to be worth US$185.9 billion, developing at a CAGR of 6.5% during the period from 2014 to 2020.

In-house API manufacturing Market in Declining Phase Due to High Level of Competition

The captive or in-house API manufacturing market and the API contract manufacturing market are the segments of the global API market based on the type of manufacturing. Hitherto, the captive API manufacturing market was the dominant segment, but, at present, the market is losing ground owing to the high level of competition coupled with decreased profitability. Correspondingly, the API contract manufacturing market is registering impressive growth.

Based on the types of API, this market is classified into the synthetic chemical API market and the biological API market, in which the biological API market is undergoing major expansion on account of the attention giant pharma companies have started to pay to this market segment.

Browse Full Press Release Report:

The API market is dominated by generic prescriptions drugs based on the types of drugs and, owing to the global volume rise in generic prescription drugs, the demand for APIs is expected to witness a swift increase across the globe.

Apart from this, the oncology drugs market is likely to report the fastest growth in the global API market in terms of therapeutic area. The growth of this market is expected to boost demand for APIs to a large extent.

API market in North America to Maintain its Dominance

The global market for API is spread across North America, Europe, Asia Pacific, and Rest of the World, wherein the market is led by North America on the account of the increasing demand for APIs in drug formulations and the rise in R&D programs. Analysts expect the region to maintain its dominance in the near future. In response to high medical and healthcare costs in the U.S., the preference for generic medicines is on the rise, fueling growth of the API market in this region. The API market in Asia Pacific stands at the second position in the geographical hierarchy of the global market, due to the presence of generic medicine producers in large numbers.

The major players in the global API market are Actavis plc, Boehringer Ingelheim Group, BASF SE, Cambrex Corporation, Hospira, Inc., Dr. Reddy’s Laboratories Ltd., Lonza Group, Novartis International AG, Mylan, Inc., Pfizer, Inc., WuXi Apptec, and Teva Pharmaceutical Industries Ltd. However, the market consists of more than 2,500 participants, making it highly fragmented in nature. The recent approval of ZarxioTM (first biosimilar in the U.S.) of Sandoz – the generic pharma division of Novartis – is expected to add significantly to overall revenue generated in the global API market.

Request a Brochure of this Report

About Us

Transparency Market Research is a global market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. Our experienced team of Analysts, Researchers, and Consultants, use proprietary data sources and various tools and techniques to gather, and analyze information.

Our data repository is continuously updated and revised by a team of research experts, so that it always reflects the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.

Contact

Mr. Nachiket
State Tower,
90 State Street,
Suite 700,
Albany NY - 12207
United States
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453
Email: sales@transparencymarketresearch.com

Website: http://www.transparencymarketresearch.com
Posted by at No comments:
Labels:

Pulmonary Arterial Hypertension Market Expected to Expand due to Rise in Incidence of Heart Failures

The global pulmonary arterial hypertension market is expected to rise proportionate to the rise in the number of heart failures. Pulmonary arterial hypertension is characterized by restrained blood flow via the pulmonary arteries, which leads to a constant increase in pulmonary vascular resistance and finally failure of the right side of the heart. PAH is one of five groups of pulmonary hypertension, as described by the World Health Organization (WHO). PAH develops due to the narrowing, blocking, and thickening of the pulmonary arteries.


Browse Full Global Pulmonary Arterial Hypertension Market Report With Complete TOC @ http://www.transparencymarketresearch.com/pulmonary-arterial-hypertension-therapeutics.html


Advanced treatment of PAH includes prostacyclin and prostacyclin analogs, phosphodiesterase-5 (PDE-5) inhibitors, endothelin receptor antagonists (ERAs) and soluble guanylate cyclase (sGC) stimulators. This leading therapy is aimed towards the symptoms of PAH and is not directed at the fundamental cause of PAH. In addition to the aforementioned classification of drugs, there are some other drugs prescribed to patients suffering from PAH, such as diuretics, calcium channel blockers, anticoagulants, and digoxin.

The pulmonary arterial hypertension (PAH) market was valued at US$4.04 billion in 2013 and is expected reach US$5.19 billion in 2020, expanding at a CAGR of 2.3% between 2014 and 2020.

Uptravi: A New Drug Application in Patients with Pulmonary Arterial Hypertension

Categorized on the basis of substantially applicable drug categories, the global pulmonary arterial hypertension (PAH) market has been segregated into prostacyclin analogs and prostacyclin, endothelin receptor antagonists (ERAs) and soluble guanylate cyclase (sGC) stimulators. Prostacyclin and prostacyclin analogs were the foremost to be medically endorsed by the U.S. FDA to treat PAH. Presently, epoprostenol Veletri and Flolan, treprostinil (Tyvaso, Remodulin, and Orenitram), and iloprost (Ventavis) are the three primary drugs in this category, and are widely used in the treatment for patients with PAH. A new drug called Uptravi, which is an assorted IP prostacyclin antagonist, is predicted to come to the fore by 2016. This new drug is expected to augment the growth of the market for prostacyclin analogs and prostacyclin through the forecast period from 2014 to 2020.


Opsumit: The Highest Selling Pulmonary Arterial Hypertension Drug

Endothelin receptor antagonists (ERAs) that disrupt the interaction between endothelin receptors and endothelin have materialized as one of the primary segments in the treatment of PAH. Tracleer (bosentan) is the foremost FDA-certified ERA. Opsumit (macitentan) and Letairis/Volibris (ambrisentan) are some other certified ERAs for the treatment of PAH. Among these, Opsumit was certified by the European Commission and the U.S. FDA in December 2013. Opsumit is predicted to materialize as the highest selling PAH drug by the end of 2020. Tracleer is set to be off-patent in Europe and the U.S. in 2017 and 2015, respectively. Patent termination of Tracleer is expected to constitute a big setback in the advancement of the ERAs market from 2014 to 2020.

Adempas: The only Certified Stimulator by the U.S. FDA to Treat Pulmonary Hypertension

Adcirca (tadalafil) from Eli Lilly/United Therapeutics Corporation and Revatio (sildenafil) from Pfizer, Inc., are the FDA-certified PDE-5 inhibitors used for the treatment of PAH. Adempas (riociguat) is the only approved sGC blockage used for the treatment of PAH. Adempas is devised for the treatment of PAH by stimulation of nitric oxide receptor sGC, which causes vasodilation, relieving the pressure on arterial walls. Adempas was first certified by the U.S. FDA in October 2013. Throughout the forecast period from 2014 to 2020, riociguat would undergo extreme competition from drugs such as treprostinil and macitentan, as all of them are meant for oral application.

Leading players in the global pulmonary arterial hypertension (PAH) market include United Therapeutics Corporation, Gilead Sciences, GSK Plc, and Actelion Pharmaceuticals, Ltd. Among these, Actelion Pharma held the biggest share in the global PAH market in 2013 thanks to its top-selling product, Tracleer (bosentan).


About Us

Transparency Market Research is a global market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. Our experienced team of Analysts, Researchers, and Consultants, use proprietary data sources and various tools and techniques to gather, and analyze information.

Our data repository is continuously updated and revised by a team of research experts, so that it always reflects the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.

Contact

Mr. Nachiket
State Tower,
90 State Street,
Suite 700,
Albany NY - 12207
United States
USA - Canada Toll Free: 866-552-3453
Email: sales@transparencymarketresearch.com

Website: http://www.transparencymarketresearch.com
Posted by at No comments:
Labels:
Subscribe to: Posts (Atom)